Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 121 to 130 of 365 total matches.
Zavegepant (Zavzpret) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
antagonists, for acute
treatment of migraine.
The Medical Letter ® Vol. 65 (1681) July 24, 2023
117 ...
The FDA has approved zavegepant nasal spray
(Zavzpret – Pfizer) for acute treatment of migraine
with or without aura in adults. Zavzpret is the first
nasal spray formulation of a calcitonin gene-related
peptide (CGRP) receptor antagonist ("gepant") to
become available in the US.
Med Lett Drugs Ther. 2023 Jul 24;65(1681):116-8 doi:10.58347/tml.2023.1681c | Show Introduction Hide Introduction
Roflumilast Foam (Zoryve) for Seborrheic Dermatitis
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
Letter ® Vol. 66 (1700) April 15, 2024
58
Table 3. Some Topical Products for Seborrheic Dermatitis1 ...
The FDA has approved a 0.3% foam formulation of
the phosphodiesterase-4 (PDE4) inhibitor roflumilast
(Zoryve – Arcutis) for topical treatment of seborrheic
dermatitis in patients ≥9 years old. Roflumilast is
the first PDE4 inhibitor to be approved in the US for
this indication. It is also available in a 0.3% cream
formulation (Zoryve) for treatment of plaque psoriasis
and in an oral formulation (Daliresp, and generics) for
treatment of chronic obstructive pulmonary disease.
A 0.15% cream formulation for treatment of atopic
dermatitis in patients ≥6 years old will be reviewed...
Med Lett Drugs Ther. 2024 Apr 15;66(1700):57-9 doi:10.58347/tml.2024.1700a | Show Introduction Hide Introduction
Daridorexant (Quviviq) for Insomnia
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022 (Issue 1654)
a
total of 1847 patients were randomized to receive
The Medical Letter ® Vol. 64 (1654) July 11, 2022 ...
The FDA has approved daridorexant (Quviviq –
Idorsia), an orexin receptor antagonist, for treatment
of sleep-onset and/or sleep-maintenance insomnia
in adults. Daridorexant is the third orexin receptor
antagonist to be approved for this indication;
suvorexant (Belsomra) and lemborexant (Dayvigo)
were approved earlier.
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • Oct 07, 2019 (Issue 1582)
The Medical Letter ® Vol. 61 (1582) October 7, 2019
They should not be used for empiric treatment of TD ...
Patients who receive pretravel advice can reduce their
risk for many travel-related conditions. Vaccines recommended
for travelers are reviewed in a separate issue.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • Dec 14, 2020 (Issue 1613)
of this material is strictly prohibited. For further information call: 800-211-2769 194 The Medical Letter ® Vol ...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations
of asthma in the emergency department is not
discussed here.
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
® Vol. 65 (1678) June 12, 2023
90
Patients of stroke, transient ischemic attack, or hemiplegic ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction
COVID-19 Update: Pfizer Bivalent Vaccine Booster Dose for Children 6 Months to 4 Years Old
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
at: www.medicalletter.org/drugs-for-covid-19.
The Medical Letter ® Vol. 65 (1674) April 17, 2023 COVID-19 Spikevax vaccines ...
The FDA has expanded its Emergency Use
Authorization (EUA) for the COVID-19 vaccine
manufactured by Pfizer/BioNTech (Comirnaty) to
permit use of the bivalent formulation (containing
mRNA from the original and BA.4/5 Omicron strains of
SARS-CoV-2) as a booster dose in children 6 months
to 4 years old who completed the primary series with
3 doses of the monovalent formulation ≥2 months
previously. The Pfizer bivalent vaccine had previously
been authorized for use as a booster dose in persons
≥5 years old and as a third primary dose in children 6
months to 4 years old. Booster...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):63-4 doi:10.58347/tml.2023.1674c | Show Introduction Hide Introduction
In Brief: Casgevy for Beta Thalassemia
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
dose is $2.2 million for
Casgevy compared to $2.8 million for Zynteglo.5
The Medical Letter ® Vol ...
Exagamglogene autotemcel (Casgevy – Vertex), a cell-based
gene therapy recently approved for treatment
of sickle cell disease1, has now been approved by
the FDA for treatment of patients ≥12 years old with
transfusion-dependent beta thalassemia. Casgevy is
the first gene therapy that uses CRISPR/Cas9 gene-editing
technology to be approved in the US for any
disorder. Betibeglogene autotemcel (Zynteglo), an
autologous lentiviral vector cell-based gene therapy,
was approved in the US in 2022 for treatment of
transfusion-dependent beta thalassemia.
Med Lett Drugs Ther. 2024 May 13;66(1702):79 doi:10.58347/tml.2024.1702d | Show Introduction Hide Introduction
Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020 (Issue 1593)
hours 5-7 hours
36
The Medical Letter ® Vol. 62 (1593) March 9, 2020
to mild or none) at 2 hours ...
Lasmiditan (Reyvow – Lilly), an oral serotonin
(5-HT1F) receptor agonist, and ubrogepant (Ubrelvy –
Allergan), an oral calcitonin gene-related peptide
(CGRP) receptor antagonist, have been approved
by the FDA for acute treatment of migraine with or
without aura in adults.
Istradefylline (Nourianz) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
.
21
The Medical Letter ® Vol. 62 (1591) February 10, 2020
Table 3. Some Drugs for Parkinson’s ...
The FDA has approved istradefylline (Nourianz —
Kyowa Kirin), an oral adenosine A2A receptor antagonist,
for use as an adjunct to carbidopa/levodopa in adults
with Parkinson's disease (PD) who experience "off"
episodes. Istradefylline is the first adenosine A2A
receptor antagonist to be approved in the US; it has
been available in Japan since 2013.